Serumske vrednosti galektina-3 i fibroblastnog faktora rasta-23 u odnosu na dijabetes tip 2 i kardiovaskularni rizik

Galectin-3 and FGF-23 in relation to diabetes and CV risk

  • Aleksandra Klisic
  • Sanja Gluscevic Clinical Center of Montenegro, Department of Neurology
  • Paschalis Karakasis Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Greece
  • Jelena Kotur-Stevuljevic Department for Medical Biochemistry, University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia
  • Ana Ninic Department for Medical Biochemistry, University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia
DOI: https://doi.org/10.5937/jomb0-50471

Sažetak


Uvod i cilj: Klinička primena galektina-3 i fibroblastnog faktora rasta-23 (FGF-23) zahteva dodatna istraživanja s obzirom da su dosadašnje studije pokazale oprečne rezultate u odnosu na dijabetes tip 2 i kardiovaskularni rizik. S tim u vezi, cilj ovog istraživanja je bio da ispita galektin-3 i FGF-23 kod pacijenata sa dijabetesom tip 2, kao i da se ispita potencijalna povezanost ovih biomarkera sa skorom aterosklerotskog kardiovaskularnog rizika (ASCVD) u adultnoj crnogorskoj populaciji.

Metode: Ukupno 35 pacijenata obolelih od dijabetesa i 36 ispitanika koji su činili kontrolnu grupu su konsekutivno uključeni u istraživanje. Serumske vrednosti galektina-3 and FGF-23 su merene ELISA metodom. ASCVD skor rizika je izračunat.

Rezultati: Veće serumske vrednosti galektina-3 su zabeležene kod pacijenata obolelih od dijabetesa tip 2 (p=0,016) u poređenju sa kontrolnom grupom. Porast nivoa galektina-3 za 1 jedinicu pokazao je 8,5% veću vjerovatnoću za pojavu dijabetesa (OR=1,085, p=0,015). Vrednosti FGF-23 se nisu razlikovale među ispitivanim grupama. Serumske vrednosti galektina-3 su korelirale sa FGF-23 (ρ=0,390, p=0,001). I galektin-3 (ρ=0,306, p=0,010) i FGF-23 (ρ=0,332, p=0,005) su korelirali sa ASCVD skorom rizika u Spearman-ovoj korelacionoj analizi, ali ove korelacije nisu zadržane u binarnoj logističkoj regresionoj analizi.

Zaključak: Serumske vrednosti galektina-3, ali ne i FGF-23 su veće kod pacijenata obolelih od dijabetesa tip 2. Serumske vrednosti galektina-3 su korelirale sa FGF-23. Premda su oba biomarkera korelirala sa ASCVD skorom rizika, dublja statistička analiza nije potvrdila nezavisnu povezanost ovih biomarkera sa kardiovaskularnim rizikom. Potrebna su istraživanja na većem broju ispitanika da dodatno istraže ulogu ovih biomarkera u dijabetesu tip 2.

Reference

1. Magliano DJ, Boyko EJ. Chapter 3, Global Picture. In IDF Diabetes Atlas 10th Edition Scientific Committee; International Diabetes Federation: Brussels, Belgium, 2021. Available online: https://www.ncbi.nlm.nih.gov/books/NBK581940/ (accessed on 10 April 2024).
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14(2):88-98. doi: 10.1038/nrendo.2017.151.
3. Klisic A, Kavaric N, Stanisic V, Vujcic S, Spasojevic-Kalimanovska V, Ninic A, Kotur-Stevuljevic J. Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes. Arch Med Sci 2019;16(1):42-50. doi: 10.5114/aoms.2019.87541.
4. Klisic A, Kotur-Stevuljevic J, Ninic A. Endocan is related to increased cardiovascular risk in type 2 diabetes mellitus patients. Metab Syndr Relat Disord 2023;21(7):362-369. doi: 10.1089/met.2023.0050.
5. Klisic A, Cojic M, Patoulias D, Ninic A. Multimarker approach as more reliable method than single vitamin D in relationship with type 2 diabetes mellitus in Montenegrin postmenopausal women. Biomedicines 2023;11:2610. https://doi.org/10.3390/biomedicines11102610.
6. Montenegro - WHO European Primary Health Care Impact, Performance and Capacity Tool (PHC-IMPACT) (2020). 14 April 2022 (https://www.who.int/andorra/publications/m/item/montenegro---who-european-primary-health-care-impact--performance-and-capacity-tool-(phc-impact)-(2020), accessed 13 April 2024).
7. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:1429–1430.
8. Golabi P, Fukui N, Paik J, Sayiner M, Mishra A, Younossi ZM. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun 2019;3:1050–60.
9. Gruson D, Maisin D, Pouleur AC, Ann SA, Rousseau MF. CA125, Galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction. EJIFCC 2023;34(2):103-109.
10. Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci 2020;21(23):9232. doi: 10.3390/ijms21239232.
11. Donate-Correa J, Martín-Núñez E, González-Luis A, Ferri CM, Luis-Rodríguez D, Tagua VG, Mora-Fernández C, Navarro-González JF. Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes. J Clin Med 2021;10(12):2583. doi: 10.3390/jcm10122583.
12. Pál K, Mănescu IB, Lupu S, Dobreanu M. Emerging Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease. Life (Basel) 2023;13(1):230. doi: 10.3390/life13010230.
13. Vora A, de Lemos JA, Ayers C, Grodin JL, Lingvay I. Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. J Clin Endocrinol Metab 2019;104(10):4449-4458. doi: 10.1210/jc.2019-00398.
14. Ohkura T, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Ohkura H, Ueta E, Kato M, Miyoshi E, Taniguchi S, Yamamoto K. Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2014;6(1):106. doi: 10.1186/1758-5996-6-106.
15. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schäffler A, Aslanidis C, Schölmerich J, Buechler C. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010;95(3):1404-11. doi: 10.1210/jc.2009-1619.
16. Echouffo-Tcheugui JB, Zhang S, Florido R, Pankow JS, Michos ED, Goldberg RB, Nambi V, Gerstenblith G, Post WS, Blumenthal RS, Ballantyne CM, Coresh J, Selvin E, Ndumele CE. Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc 2024;13(6):e031607. doi: 10.1161/JAHA.123.031607.
17. Atalar MN, Abuşoğlu S, Ünlü A, Tok O, İpekçi SH, Baldane S, Kebapcılar L. Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes. Life Sci 2019;231:116577. doi: 10.1016/j.lfs.2019.116577.
18. Mosavat M, Omar SZ, Sthanshewar P. Serum FGF-21 and FGF-23 in association with gestational diabetes: a longitudinal case-control study. Horm Mol Biol Clin Investig 2020;41(2). doi: 10.1515/hmbci-2019-0060.
19. Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz D, Sztefko K, Starzyk JB. The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab 2012;25(7-8):687-90. doi: 10.1515/jpem-2012-0064.
20. Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 2015;10(3):e0122885. doi: 10.1371/journal.pone.0122885.
21. Liu Y, Guan S, Xu H, Zhang N, Huang M, Liu Z. Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis. Front Cardiovasc Med 2023;10:1175174. doi: 10.3389/fcvm.2023.1175174.
22. Kurpas A, Supel K, Wieczorkiewicz P, Bodalska Duleba J, Zielinska M. Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients-Cardiologists Be Aware. Metabolites 2022;12(6):498. doi: 10.3390/metabo12060498.
23. Tuñón J, Fernández-Fernández B, Carda R, Pello AM, Cristóbal C, Tarín N, Aceña Á, González-Casaus ML, Huelmos A, Alonso J, Lorenzo Ó, González-Parra E, Hernández-González I, Mahíllo-Fernández I, López-Bescós L, Egido J. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. Diabetes Metab Res Rev 2016;32(7):685-693. doi: 10.1002/dmrr.2787.
24. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40:S11–S24.
25. Petrovic I, Pejnovic N, Ljujic B, Pavlovic S, Miletic Kovacevic M, Jeftic I, Djukic A, Draginic N, Andjic M, Arsenijevic N, Lukic ML, Jovicic N. Overexpression of Galectin 3 in Pancreatic β Cells Amplifies β-Cell Apoptosis and Islet Inflammation in Type-2 Diabetes in Mice. Front Endocrinol (Lausanne) 2020;11:30. doi: 10.3389/fendo.2020.00030.
26. van der Vaart A, Yeung SMH, van Dijk PR, Bakker SJL, de Borst MH. Phosphate and fibroblast growth factor 23 in diabetes. Clin Sci (Lond) 2021;135(14):1669-1687. doi: 10.1042/CS20201290.
27. Bär L, Feger M, Fajol A, Klotz LO, Zeng S, Lang F, Hocher B, Föller M. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci U S A 2018;115(22):5804-5809. doi: 10.1073/pnas.1800160115.
28. Paul S, Wong M, Akhabue E, Mehta RC, Kramer H, Isakova T, Carnethon MR, Wolf M, Gutiérrez OM. Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults. J Am Heart Assoc 2021;10(16):e020196. doi: 10.1161/JAHA.120.020196.
29. Karady J, Ferencik M, Mayrhofer T, Meyersohn NM, Bittner DO, Staziaki PV, et al. Risk factors for cardiovascular disease among individuals with hepatic steatosis. Hepatol Commun 2022;6:3406–3420. https://doi. org/10.1002/hep4.2090
Objavljeno
2024/10/03
Broj časopisa
Vol. 44 Br. 1 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2024 Aleksandra Klisic, Sanja Gluscevic, Paschalis Karakasis, Jelena Kotur-Stevuljevic, Ana Ninic

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.